GRAMEGNA, ANDREA
GRAMEGNA, ANDREA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Beta cell function and insulin sensitivity during elexacaftor/tezacaftor/ivacaftor therapy in people with cystic fibrosis
2026 L. Zazzeron, V. Grancini, M. Trombetta, G. Alicandro, M.L. Boselli, I. Cogliati, G. Mantovani, A. Gramegna, F. Blasi, R.C. Bonadonna, E. Orsi, V. Daccò
Core outcome set for trials evaluating the management of community-acquired and nosocomial pneumonia in adults: an ERS statement
2026 M. Fally, C. Cilloniz, J. Linnell, S. Aliberti, A. Barac, F. Blasi, A. Cumber, P. Dilorenzo, G. Dimopoulos, C. Gainer, W.H. Van Geffen, A. Gramegna, B. Hoehn, E. Polverino, C. Roger, N. Rovina, D. Stolz, G. Waterer, C. Williams, D. Wootton, A.G. Mathioudakis, T.W. Felton
Clinical profile and in-hospital outcomes of patients hospitalised for bronchiectasis exacerbation
2026 F. Bindo, E. Simonetta, A. Gramegna, P. Faverio, P. Scarano, V. Polelli, A. Stainer, F. Amati, M. Nigro, A. Tramontano, S. Mirijaj, P. Curci, M. Mancuso, C. Crimi, F. Luppi, F. Blasi, S. Aliberti
Evaluating current bronchiectasis care in Italy according to the 2025 European respiratory society recommendations
2026 A. De Angelis, V. Comellini, A. Gramegna, S. Battaglia, G. Montemurro, A. Bellofiore, F. Pagnini, E. Privitera, M. Ori, E. Simonetta, M. Nigro, J.D. Chalmers, D. Nobile, F. Blasi, S. Aliberti
Nutritional outcomes in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor: A 24-month real-world study
2026 G. Alicandro, L. Zazzeron, V. Visciola, A. Bulfamante, A. Biffi, F. Corti, A. Gramegna, F. Blasi, V. Daccò
Nonpharmacological interventions for managing infections in chronic respiratory diseases: a comprehensive overview
2026 C. Premuda, M. Santambrogio, S. Misuraca, G. Putti, F. Maraz, A. Sarassi, A. Bulfamante, F. Blasi, A. Gramegna
Determinants of time to decannulation and predictors of early weaning from tracheostomy: a multicenter, retrospective Italian cohort study
2026 D. Radovanovic, F. Di Marco, M. Mondoni, C. Crimi, A. Gramegna, M. Gatti, J.C. Signorello, F. Raimondi, C. Albrici, G. Morana, F.B.A. Blasi, P. Santus
Pharmacotherapy options and drug development in bronchiectasis: spotlight on dipeptidyl-peptidase inhibitors
2026 C. Premuda, A. Gramegna, S. Misuraca, F. Piedepalumbo, L. Terranova, M. Santambrogio, M. Contarini, M. Ori, F. Blasi
Bronchiectasis in Italy: an analysis of the EMBARC registry
2026 S. Aliberti, A. Gramegna, E. Simonetta, A. De Angelis, M. Nigro, A. Stainer, F. Amati, S. Battaglia, G. Sotgiu, F. Dente, P. Faverio, O. Sibila, M. Shteinberg, M. Vendrell, K. Dimakou, A. Amorim, E. Polverino, S. Borekci, E. Gerada, J. Pollock, K. Robertson, V. Polelli, M. Santambrogio, M. Retucci, D. Nobile, J.D. Chalmers, F. Blasi
Tackling Neutrophilic Inflammation in Bronchiectasis: From Macrolides to Cathepsin C Inhibitors
2026 A. Gramegna, C. Premuda, G. Putti, F. Piedepalumbo, S. Misuraca, M. Ori, M. Nigro, E. Simonetta, S. Aliberti, F. Blasi
Prevalence, type, and clinical implications of CFTR variants in bronchiectasis
2026 A. Gramegna, L. Allavena, G. Alicandro, E. Canella, M. Nigro, C. Premuda, M. Ori, M. Santambrogio, L. Porcaro, D. Prati, L. Valenti, S. Aliberti, F. Blasi
Validation of the Italian version of Bronchiectasis Quality of Life Questionnaire
2026 E. Franceschi, A. De Angelis, A. Gramegna, I. Baiardini, E. Simonetta, M. Nigro, A. Stainer, V. Polelli, F. Bini, F. Braido, F. Blasi, S. Aliberti
Determinants of early Elexacaftor-Tezacaftor-Ivacaftor use in adults with cystic fibrosis and preserved lung function: insights from a European multicenter survey
2026 A. Gramegna, C. Magnoni, C. Premuda, G. Alicandro, O. Akkerman, A. Amorim, P. Azevedo, S. Bourke, V. Carnovale, F. Diamantea, L. Fila, F. Frost, R.M. Giron Moreno, C. Pescaru, E. Polverino, A. Felipe Montiel, M. Rachel, G.P. Stoyanova, E. Van Braeckel, S. Volpi, A. Vukić-Dugac, S. Wege, N.J. Simmonds, B.J. Plant, D.G. Downey, S. van Koningsbruggen-Rietschel, P. Burgel, F. Blasi
Cystic Fibrosis
2025 S. Misuraca, A. Gramegna, F. Blasi
Impact of long-term high-flow nasal therapy on mucus plugs in patients with bronchiectasis
2025 C. Crimi, S. Nolasco, R. Campisi, M. Nigro, P. Impellizzeri, A. Cortegiani, A. Noto, A. Gramegna, C. Vancheri, F. Blasi, N. Crimi, S. Aliberti, A. Carlucci
Prevalence and types of treatable traits in bronchiectasis: a multicentre, cross-sectional study
2025 M. Cicchetti, A. De Angelis, E. Simonetta, A. Gramegna, P. Faverio, M. Contarini, F. Amati, V.A. Artuso, A. Tramontano, M. Nigro, P. Scarano, V. Polelli, G.E. Carpagnano, F. Luppi, F. Blasi, S. Aliberti
Comparison of n-Butyl-2-Cyanoacrylate and Tris-Acryl Microspheres for Bronchial Artery Embolization in Patients with Cystic Fibrosis and Hemoptysis: A Retrospective Cohort Study
2025 A.M. Ierardi, V. Ascenti, A. Gramegna, F. Blasi, C. Del Giudice, G. Xhepa, F. Del Grande, M. Venturini, G. Carrafiello, A. Coppola
Respiratory Outcomes and Aspergillus Serology Following Elexacaftor/Tezacaftor/Ivacaftor Therapy in People with Cystic Fibrosis and a History of Aspergillus fumigatus Infection
2025 C. Lanfranchi, G. Alicandro, L. Cariani, B.S. Orena, A. Gramegna, C. Rizza, F. Blasi, V. Daccò
Awareness of respiratory syncytial virus and other respiratory disease vaccines among healthcare professionals and their patients in Italy: Insights from a literature review and a web-based survey
2025 C. Micheletto, G. Lorenzini, S. De Grazia, F. Di Marco, R. Di Matteo, P. Faverio, A. Gramegna, M. Vicentini, F. Blasi
How do climate conditions and urbanisation impact nontuberculous mycobacterial infections? An Italian nationwide case–control study
2025 P. Faverio, L. Del Castello, M. Spotti, P. Rebora, E.C. Maggioni, R. Salerno, A. Perotto, F. Luppi, F.R. Bertuccio, S. Reale, V. Fornari, F. Gozzi, B. Granozzi, F.L. Dente, F. Mariotti, J. Simonetti, G. Gualano, N. Riccardi, M. Ferrarese, L.R. Codecasa, G. Sotgiu, A. Gori, A. Gramegna, M. Ori, E. Simonetta, F. Blasi, S. Aliberti